Literature DB >> 33946817

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test.

Anna Colombo1, Mauro Giuffrè1, Lory Saveria Crocè1, Sergio Venturini2, Renato Sablich3.   

Abstract

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies.

Entities:  

Keywords:  Infliximab; Quantiferon; inflammatory bowel disease; peritoneal tuberculosis

Year:  2021        PMID： 33946817     DOI： 10.3390/pathogens10050535

Source DB:  PubMed          Journal:  Pathogens        ISSN： 2076-0817


  22 in total

1.  Primary tuberculous peritonitis during infliximab therapy for Crohn's disease.

Authors:  Ulrich Bonse-Geuking; Michael Kraus
Journal:  J Crohns Colitis       Date:  2012-02-27       Impact factor: 9.071

2.  Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.

Authors:  Chrisoula Hatzara; Emilia Hadziyannis; Anna Kandili; Christos Koutsianas; Anastasia Makris; Georgios Georgiopoulos; Dimitrios Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2014-05-22       Impact factor: 19.103

3.  Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis.

Authors:  Yu Kyung Jun; Jaeyoung Chun; Eun Ae Kang; Hyun Jung Lee; Jong Pil Im; Joo Sung Kim
Journal:  Korean J Gastroenterol       Date:  2019-09-25

4.  Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment.

Authors:  M Bocchino; A Matarese; B Bellofiore; P Giacomelli; G Santoro; N Balato; F Castiglione; R Scarpa; F Perna; G Signoriello; D Galati; A Ponticiello; A Sanduzzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-10       Impact factor: 3.267

Review 5.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.

Authors:  Yael Abitbol; David Laharie; Jacques Cosnes; Matthieu Allez; Stéphane Nancey; Aurélien Amiot; Alexandre Aubourg; Mathurin Fumery; Romain Altwegg; Pierre Michetti; Elise Chanteloup; Philippe Seksik; Clotilde Baudry; Mathurin Flamant; Guillaume Bouguen; Carmen Stefanescu; Anne Bourrier; Gilles Bommelaer; Nina Dib; Marc André Bigard; Stephanie Viennot; Xavier Hébuterne; Jean-Marc Gornet; Philippe Marteau; Yoram Bouhnik; Vered Abitbol; Stéphane Nahon
Journal:  J Crohns Colitis       Date:  2016-07-11       Impact factor: 9.071

Review 7.  Latent tuberculosis infection: myths, models, and molecular mechanisms.

Authors:  Noton K Dutta; Petros C Karakousis
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

8.  The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.

Authors:  Giovanna Cuomo; Virginia D’Abrosca; Daniela Iacono; Ilenia Pantano
Journal:  Clin Rheumatol       Date:  2016-11-05       Impact factor: 2.980

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

10.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

Authors:  Fernando Magro; Paolo Gionchetti; Rami Eliakim; Sandro Ardizzone; Alessandro Armuzzi; Manuel Barreiro-de Acosta; Johan Burisch; Krisztina B Gecse; Ailsa L Hart; Pieter Hindryckx; Cord Langner; Jimmy K Limdi; Gianluca Pellino; Edyta Zagórowicz; Tim Raine; Marcus Harbord; Florian Rieder
Journal:  J Crohns Colitis       Date:  2017-06-01       Impact factor: 10.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.